Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPDNew phase 2 data for amlitelimab show ...

Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for ...

Sanofi (Nasdaq: SNY) with We Are ILL, Inc., visits the Nasdaq MarketSite in Times Square. A patient advocacy organization, We Are ILL redefines what “sick” looks like by making the multiple ...

LONDON The £10,000 Aventis Prize for Science Books — sometimes called science's Booker Prize — has this year been won by Robert Kunzig's Mapping the Deep – The Extraordinary Story of Ocean Science.

MLB Opening Day 2025 is finally upon us and all eyes will be on the Los Angeles Dodgers after their World Series win in 2024. The Dodgers technically already opened their season with a sweep of ...

Sanofi has managed the daunting task faced by managers worldwide: hauling its employees back to the office with minimal fuss. That’s an impressive feat for a company that said last year it was ...

Image credit: Shutterstock / Wirestock Creators. The US Food and Drug Administration (FDA) has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia ...

(IN BRIEF) Sanofi’s mRNA vaccine candidate for chlamydia has been granted fast track designation by the US FDA, reflecting its promising potential to address a significant public health issue.

Goldman Sachs initiated coverage of Sanofi (SNY) with a Neutral rating and $65 price target While the firm sees Sanofi emerging as a pipeline story, it believes this is somewhat reflected at ...

Paris: Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific ...

Sanofi (NASDAQ:SNY) has agreed to acquire an immunology drug from clinical-stage biopharmaceutical company Dren Bio for up to $1.9B. The French pharmaceutical company will acquire DR-0201, a CD20 ...

Sanofi SNY announced that it signed an agreement with California-based privately held biopharmaceutical company Dren Bio to acquire the latter’s investigational bispecific antibody DR-0201.